News
-
-
-
-
PRESS RELEASE
Success of the sales diversification strategy in the first quarter of 2026 and commercial launches of the new BioSolutions
Fermentalg achieves record turnover of €3.7 million in Q1 2026, with 42% sales growth excluding aquaculture. Positive outlook with rising fish oil prices and upcoming product launches -
-
-
-
-
PRESS RELEASE
2025 Annual Results: Strong sales growth, expansion of the customer portfolio and BioSolutions, and strengthening of the financial structure thanks to Huvepharma
Fermentalg reports a record 2025 turnover of €13.4 million, stable operating profit, post-closing loan from Huvepharma, promising outlook with new product launches, and a target of €20 million revenue by 2026 -
